Proteins and Peptides

07 Jan 2017 LFB S.A. Announced Today the Acceptance by U.S. Food and Drug Administration of the Filed Biologic License Application for Coagulation Factor VIIa Recombinant, (eptacog beta activated)
05 Jan 2017 Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)
05 Jan 2017 XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjögren's Syndrome
05 Jan 2017 Novaliq Announces Positive Topline Results of Phase 2 Clinical Trial Evaluating CyclASol® in Adults with Moderate to Severe Dry Eye Disease
05 Jan 2017 Halozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints
05 Jan 2017 Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen™
04 Jan 2017 Tarveda Therapeutics Announces Phase 1/2a Clinical Trial of PEN-221 Underway in Patients with Neuroendocrine Tumors and Small Cell Lung Cancer
04 Jan 2017 Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera™ for Treatment of Dry Eye
01 Jan 2017 OPKO Health Provides Update on hGH-CTP Clinical Programs
29 Dec 2016 Anthera Announces the Phase 3 SOLUTION Study with Sollpura™ in Cystic Fibrosis Patients with Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results - Additional Study Needed
27 Dec 2016 Shire Announces FDA Approval of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] for use in Children and Surgical Settings
23 Dec 2016 Novelion Therapeutics’ Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy
23 Dec 2016 Protalix BioTherapeutics Announces Last Patient Enrolled in the AIR DNase™ Phase II Clinical Trial for Cystic Fibrosis
23 Dec 2016 Synergy Pharmaceuticals Announces Positive Results in Second Phase 3 Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
22 Dec 2016 AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency
21 Dec 2016 DiaMedica Announces Positive Top-Line Results from DM199 Bridging Clinical Trial
21 Dec 2016 Factor Therapeutics Announces Commencement of Phase II Trial of a Novel Topical Biologic for the Treatment of Chronic Wounds
21 Dec 2016 Hansa Medical Discontinues its Phase II Study in Acquired Thrombotic Thrombocytopenic Purpura (TTP)
19 Dec 2016 Antares Pharma Announces the Successful Completion of Teva’s Decentralized Procedure for Teriparatide Injection in Europe
19 Dec 2016 IND submission to initiate clinical trials of NB 1001 (XTEN-GLP1) for treatment of Short Bowel Syndrome announced by Naia Rare Diseases
19 Dec 2016 Ferring and IMAB Sign Licensing Agreement Granting IMAB Exclusive Rights in Asia to Olamkicept for the Treatment of Autoimmune Disease
19 Dec 2016 ProMetic initiates rolling submission of its Biologics License Application ("BLA") for plasminogen with U.S. FDA
17 Dec 2016 Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro in people with type 1 diabetes
16 Dec 2016 Significant Improvements in Knee Function after TPX-100 Administration in a Double-Blind, Placebo-Controlled Phase 2 Study of Knee Osteoarthritis
13 Dec 2016 Ferring Receives EU Approval for REKOVELLE® (follitropin delta)

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing